JZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathy. - Wikidata - awgldk - TriplyDB

JZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathy.

JZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathy.

http://www.wikidata.org/entity/Q34715335

about

The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain.Peripherally Restricted Cannabinoids for the Treatment of Pain.Evaluation of different drug classes on transient sciatic nerve injury-depressed marble burying in mice.Cannabinoids and agmatine as potential therapeutic alternatives for cisplatin-induced peripheral neuropathy.Targeting the Endocannabinoid System for Prevention or Treatment of Chemotherapy-Induced Neuropathic Pain: Studies in Animal Models 2-arachidonyl glycerol modulates astrocytic glutamine synthetase via p38 and ERK1/2 pathways

P2860

Q38600704-AFFF5839-3DA2-4D39-BF8B-C8961AE4BE44 Q38615325-759C9AAA-89E9-4064-A0AA-009DEF7BB33F Q52660821-790BB678-F954-41E8-B413-2BDA279A83B5 Q55340197-9E2FFC0E-4DB6-444F-868C-E12D46706458 Q57174777-F0EED709-67FC-46BB-BBA1-6A4BD7619E8C Q58801297-9A6E4D4C-4407-41E5-BF05-50DCB81DC604

P2860

JZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathy.

http://www.wikidata.org/entity/Q34715335

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

JZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathy.

@ast

JZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathy.

@en

JZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathy.

@nl

type

label

JZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathy.

@ast

JZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathy.

@en

JZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathy.

@nl

prefLabel

JZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathy.

@ast

JZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathy.

@en

JZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathy.

@nl

P1433

Q34715335-CD7619C6-9B11-4418-AAB7-C7F7E2B05BB3

P1476

Q34715335-8ABF63CA-D10B-43BE-B2F5-89804A5135AE

P2093

Q34715335-09822AC6-3174-4D1E-8774-BD46F06BBE35

Q34715335-38FF958B-1D6C-438A-A5D8-D1F608F27DD8

Q34715335-393EF7B6-C388-436F-8750-483436158B44

Q34715335-90F9BC33-FDCD-4DA9-8D20-39E2D90793E5

Q34715335-BEC19434-E4C1-4995-BDD2-410B67E4B028

Q34715335-BF02AAD6-9203-41D8-BBD0-E6A1E68146E3

Q34715335-C676F388-FCCB-49F2-961D-33F07F1DCA0D

Q34715335-C9C4324C-1247-4974-9DF8-50543EDFE65C

Q34715335-E6515FBA-3789-4F3E-A75A-9DD03E44889E

P2860

Q34715335-15A85A41-8740-44D6-9D42-1F0C4CF3C55E

Q34715335-210C0A6F-C266-446F-9019-616F15C2B29E

Q34715335-24C44868-675D-4E67-97E7-408DB9C635EE

Q34715335-2C60039C-D27A-4311-9C58-EBEC959D0380

Q34715335-2FF24F3C-3D81-40B8-A72A-44AA5C51B1D9

Q34715335-307C1ED7-CCD5-4667-8939-BE617B984349

Q34715335-32E32BE1-8946-4822-A671-A068F499CCEB

Q34715335-34AFBD83-A85B-4FB7-9A7E-DD6DDF60D6E7

Q34715335-45F49BA9-D162-43D2-ABAC-9ECE74D58CBE

Q34715335-4774E1FE-9D63-430E-A334-878160F5A56C

P304

Q34715335-935CA597-DE27-4BBA-BD1E-EDB81BA752F2

P31

Q34715335-9E900B21-2529-4D4D-AB92-61E36EB17A15

P356

Q34715335-D17EB39D-87AE-4F94-A57C-9E53CF95C327

P478

Q34715335-796D2D9E-94F5-46C7-80EB-92501A523F46

P577

Q34715335-38EBD09A-AFE3-4253-97A2-CC5B5B4C0B4D

P698

Q34715335-023454CA-28D9-4F64-A824-634818E0FFC6

P932

Q34715335-9596C17F-8D7B-4EE1-85DE-8835C26204AB

P356

J.PHRS.2014.09.008

P1433

Pharmacological Research

P1476

JZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathy.

@en

P2093

Amy E Lindberg

http://www.w3.org/2001/XMLSchema#string

Cutler T Lewandowski

http://www.w3.org/2001/XMLSchema#string

Don A Simone

http://www.w3.org/2001/XMLSchema#string

Iryna A Khasabova

http://www.w3.org/2001/XMLSchema#string

Justin Paz

http://www.w3.org/2001/XMLSchema#string

Lia Coicou

http://www.w3.org/2001/XMLSchema#string

Natasha Burlakova

http://www.w3.org/2001/XMLSchema#string

Virginia S Seybold

http://www.w3.org/2001/XMLSchema#string

Xu Yao

http://www.w3.org/2001/XMLSchema#string

P2860

Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects

Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain

Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630

A new mathematical model for relative quantification in real-time RT-PCR

Mode of action of cannabinoids on nociceptive nerve endings

Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand

Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system.

The inhibition of monoacylglycerol lipase by URB602 showed an anti-inflammatory and anti-nociceptive effect in a murine model of acute inflammation

Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol.

Fatty acid amide hydrolase and monoacylglycerol lipase inhibitors produce anti-allodynic effects in mice through distinct cannabinoid receptor mechanisms.

P304

67-75

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.PHRS.2014.09.008

http://www.w3.org/2001/XMLSchema#string

P478

90

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25304184

http://www.w3.org/2001/XMLSchema#string

P932

4268146

http://www.w3.org/2001/XMLSchema#string